My Fulbright research aims to develop and expand innovative cell-based therapies for neonatal conditions that cause lifelong disability in vulnerable infants. By strengthening U.S.–Australia collaborations and conducting rigorous clinical trials, this work seeks to translate cord blood–derived therapies into safe, effective treatments that improve long-term health and developmental outcomes.
Dr Atul Malhotra, MD, PhD is a clinician–scientist and Professor at Monash University, internationally recognized for his leadership in cord blood and stem cell research in newborn infants. His work focuses on translating stem and immune cell therapies from bench to bedside, with a strong emphasis on rigorous clinical trials to evaluate safety and efficacy in neonatal conditions. Through large-scale clinical studies and international collaborations, Dr Malhotra aims to harness cord blood–derived cells to reduce lifelong disability and improve outcomes for vulnerable infants.
During his Fulbright Scholarship, Atul will advance his U.S. collaboration with key stakeholders and institutions, accelerating high-impact research with global clinical relevance.